Upadacitinib + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ankylosing Spondylitis (AS)
Conditions
Ankylosing Spondylitis (AS)
Trial Timeline
Oct 24, 2017 → Feb 17, 2022
NCT ID
NCT03178487About Upadacitinib + Placebo
Upadacitinib + Placebo is a phase 2 stage product being developed by AbbVie for Ankylosing Spondylitis (AS). The current trial status is completed. This product is registered under clinical trial identifier NCT03178487. Target conditions include Ankylosing Spondylitis (AS).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06118411 | Phase 3 | Active |
| NCT06012240 | Phase 3 | Recruiting |
| NCT05843643 | Phase 3 | Recruiting |
| NCT05889182 | Phase 3 | Recruiting |
| NCT04927975 | Phase 2 | Completed |
| NCT04430855 | Phase 2 | Completed |
| NCT04169373 | Phase 3 | Completed |
| NCT02955212 | Phase 3 | Completed |
| NCT03178487 | Phase 2 | Completed |
| NCT02925117 | Phase 2 | Completed |
Competing Products
20 competing products in Ankylosing Spondylitis (AS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Infliximab | Celltrion | Phase 1 | 33 |
| Infliximab | Celltrion | Phase 1 | 33 |
| SUNPG1622 I dose + Placebo dose | Sun Pharmaceutical | Phase 2 | 52 |
| adalimumab | Eisai | Phase 3 | 77 |
| Ixekizumab + Placebo + Adalimumab | Eli Lilly | Phase 3 | 77 |
| Tramadol /acetaminophen + Diclofenac | Johnson & Johnson | Approved | 85 |
| Golimumab + Placebo | Johnson & Johnson | Phase 3 | 77 |
| Golimumab | Johnson & Johnson | Approved | 85 |
| SHR0302 + SHR0302 placebo | Jiangsu Hengrui Medicine | Phase 2/3 | 65 |
| placebo for risankizumab + risankizumab | AbbVie | Phase 2 | 52 |
| Adalimumab | AbbVie | Approved | 85 |
| Adalimumab | AbbVie | Pre-clinical | 23 |
| infliximab + Placebo | Merck | Phase 3 | 77 |
| Infliximab | Merck | Approved | 85 |
| Infliximab + Placebo + Naproxen | Merck | Phase 3 | 77 |
| Infliximab | Merck | Pre-clinical | 23 |
| Golimumab | Merck | Approved | 85 |
| Remicade | Merck | Approved | 85 |
| Remicade | Merck | Approved | 85 |
| Infliximab | Merck | Approved | 85 |